A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been ...

BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...

Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.

The Federal Trade Commission is praising an appeals court decision calling for Teva to delist five inhaler patents from the ...

Amgen, Eli Lilly and UCB sued the federal government, claiming that several STD clinics getting drug discounts under the ...

Applied Therapeutics CEO Shendelman exits; CFO Funtleyder becomes interim CEO after FDA rejects govorestat. Company withdraws ...

Employees Nos. 1 and 2 of the $4.6 billion health tech startup Color Health have started their own company, aiming to tackle ...

Bristol Myers Squibb's Sotyktu succeeds in Phase 3 psoriatic arthritis trials, as company leads TYK2 race against Takeda & ...

The Centers for Medicare and Medicaid Services on Friday released detailed but heavily redacted explanations of how it ...

Sumitomo Pharma’s oral treatment for overactive bladder symptoms has won an expanded label from the FDA, and is now approved ...

Novo Nordisk's CagriSema fell short of weight loss goals, causing 17% stock drop. Drug shows similar results to Eli Lilly's ...

The FDA on Friday issued two simultaneous cystic fibrosis approvals for Vertex Pharmaceuticals, but included boxed safety ...